Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
137.25
-1.66 (-1.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
469,545
Open
139.10
Bid (Size)
136.95 (1)
Ask (Size)
139.56 (1)
Prev. Close
138.91
Today's Range
136.80 - 140.10
52wk Range
55.25 - 173.25
Shares Outstanding
93,148,652
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
August 19, 2024
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.
Via
MarketBeat
How Is The Market Feeling About Sarepta Therapeutics?
August 16, 2024
Via
Benzinga
Performance
YTD
+42.66%
+42.66%
1 Month
-4.05%
-4.05%
3 Month
+10.29%
+10.29%
6 Month
+7.31%
+7.31%
1 Year
+14.63%
+14.63%
More News
Read More
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
August 15, 2024
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
August 12, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in August
August 12, 2024
Via
The Motley Fool
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
August 11, 2024
Via
Benzinga
Smart Money Is Betting Big In SRPT Options
August 08, 2024
Via
Benzinga
NASDAQ:SRPT may be ready to breakout.
August 02, 2024
Via
Chartmill
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
August 09, 2024
Via
Investor's Business Daily
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
August 08, 2024
Via
Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Via
InvestorPlace
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
August 08, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 07, 2024
Via
InvestorPlace
26 Analysts Have This To Say About Sarepta Therapeutics
July 29, 2024
Via
Benzinga
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
July 18, 2024
Via
Benzinga
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
July 04, 2024
Via
Benzinga
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
August 07, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
3 Genomics Stocks That May Transform Personalized Medicine
August 06, 2024
Via
InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
July 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
July 17, 2024
Via
InvestorPlace
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
July 17, 2024
Via
Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
July 17, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
July 06, 2024
Via
The Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
July 04, 2024
Via
The Motley Fool
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.